Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ABBV-453 |
Synonyms | |
Therapy Description |
ABBV-453 inhibits BCL2, potentially leading to increased tumor cell apoptosis (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-453 | ABBV 453|ABBV453 | BCL2 inhibitor 27 | ABBV-453 inhibits BCL2, potentially leading to increased tumor cell apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05308654 | Phase I | ABBV-453 | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets | Active, not recruiting | USA | ISR | GBR | AUS | 0 |
NCT06291220 | Phase I | Obinutuzumab ABBV-453 | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Recruiting | USA | ISR | DEU | AUS | 0 |